Dr. Bilcer has almost 20 years experience working in the aspartic protease field with more than a decade in the pharmaceutical industry. In 2003, as a founding member of Zapaq, Inc., a predecessor to CoMentis, he directed the medicinal chemistry group in their discovery of BACE inhibitors for the treatment of Alzheimer’s disease. This work resulted in the first BACE inhibitor to enter human clinical trials. He was promoted to Vice President in 2010 as he continued to oversee the company’s medicinal chemistry efforts both in the US and with partners in Japan. Dr. Bilcer is also responsible for maintaining the company’s extensive patent portfolio as well as overseeing the discovery efforts for the Alpharmagen α7 nicotinic acetylcholine receptor projects.
Dr. Bilcer completed his BA degree in chemistry at Northwestern University and his Ph.D. at the University of Illinois at Chicago. He is a co-author on more than 15 scientific publications as well as an inventor on numerous patents in the US and worldwide.